
After a $100 Haircut, is Catalent an Oversold Pharma Play?
Published on November 14, 2022
With the macro backdrop weakening for Catalent’s pharmaceutical and biotech customers, fundamental concerns could outweigh what the charts suggest.

With the macro backdrop weakening for Catalent’s pharmaceutical and biotech customers, fundamental concerns could outweigh what the charts suggest.